Enveric Biosciences, Inc. (ENVB)
$6.69
-0.09 (-1.33%)
Rating:
Recommendation:
-
| Symbol | ENVB |
|---|---|
| Price | $6.69 |
| Beta | 0.000 |
| Volume Avg. | 0.28M |
| Market Cap | 10.397M |
| Shares () | - |
| 52 Week Range | 5.9-187.0 |
| 1y Target Est | - |
| DCF Unlevered | ENVB DCF -> | |
|---|---|---|
| DCF Levered | ENVB LDCF -> | |
| ROE | -203.26% | Strong Sell |
| ROA | -182.75% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | 934.93% | Strong Buy |
| P/E | - | |
| P/B | 11.04 | Strong Buy |
Latest ENVB news
About
Download (Excel)Enveric Biosciences, Inc., a pharmaceutical company, engages in developing various cannabinoid medicines for cancer care. Its products pipeline includes EV104 for the treatment of osteoarthritis; EVM-101 and EVM-201 for the treatment of cancer related distress; EVM-301 for the treatment of mental health indication; EV102, a cannabinoid cream for topical skin application; and EV101, a cannabinoid and chemotherapy combination therapy. Enveric Biosciences, Inc. is headquartered in Naples, Florida.